Mesirow Financial Investment Management Inc. Trims Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Mesirow Financial Investment Management Inc. reduced its stake in Thermo Fisher Scientific by 3.1%, selling 2,793 shares, which leaves them with a total of 88,048 shares valued at approximately $43.8 million.
• Thermo Fisher Scientific reported a quarterly EPS of $5.36, surpassing analysts' estimates of $5.22, with year-over-year revenue growth of 2.9% to $10.86 billion.
• The company announced a quarterly dividend of $0.43 per share, reflecting an annual dividend yield of 0.36% and a payout ratio of 9.95%.

Mesirow Financial Investment Management Inc. lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 88,048 shares of the medical research company's stock after selling 2,793 shares during the quarter. Thermo Fisher Scientific comprises 0.8% of Mesirow Financial Investment Management Inc.'s portfolio, making the stock its 23rd biggest holding. Mesirow Financial Investment Management Inc.'s holdings in Thermo Fisher Scientific were worth $43,813,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Brighton Jones LLC grew its holdings in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its holdings in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after purchasing an additional 461 shares during the period. New Age Alpha Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $48,000. Finally, Geode Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock worth $4,075,540,000 after acquiring an additional 197,442 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research analyst reports. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Argus dropped their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Royal Bank Of Canada cut their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, HSBC restated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Six investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $9.72 during trading hours on Thursday, hitting $467.56. 3,413,838 shares of the company's stock were exchanged, compared to its average volume of 3,120,658. The firm has a market cap of $176.50 billion, a P/E ratio of 27.04, a P/E/G ratio of 2.55 and a beta of 0.77. The firm has a 50 day moving average of $418.15 and a two-hundred day moving average of $468.92. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.37 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.